Amy Walker

Overview

CEO of Forbase Bio, UK-based pioneer in cell-free enzymatic DNA manufacturing at GMP grade for cell and gene therapy, advocating scale-out over scale-up for personalized medicine. Amy Walker serves as CEO of Forbase Bio, a UK-based company producing enzymatic DNA at GMP grade to displace plasmid DNA as a critical starting material in cell and gene therapy, vaccines, and gene editing applications. Walker identifies a capacity disconnect in the cell and gene therapy industry: while industry capacity exists for hundreds or thousands of liters of viral vectors or plasmid DNA, actual clinical program needs are far more modest, and a significant portion of the industry remains in very early, nascent stages. (Segment 2 (05:00-10:00))